Explore the words cloud of the GlucoBeam project. It provides you a very rough idea of what is the project "GlucoBeam" about.
The following table provides information about the project.
RSP SYSTEMS A/S
|Coordinator Country||Denmark [DK]|
|Total cost||5˙219˙875 €|
|EC max contribution||2˙348˙943 € (45%)|
1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
|Duration (year-month-day)||from 2017-03-01 to 2019-08-31|
Take a look of project's partnership.
|1||RSP SYSTEMS A/S||DK (ODENSE S)||coordinator||2˙348˙943.00|
Diabetes mellitus (DM) is one of the largest health challenges currently faced by modern society, affecting over 400 million people in the world. DM cannot be cured, but via well-controlled therapy, a high quality of life with diabetes can be obtained, with a minimum of short- and long-term complications. The key to a successful diabetes therapy is a well-controlled blood glucose level, which is obtained by carefully balancing insulin intake, diet, and exercise and with Self-Monitoring of Blood Glucose (SMBG) as a cornerstone. Conventional SMBG is an invasive test requiring the patient to prick his/her finger with a lancet to extract a blood droplet onto a disposable strip for electrochemical analysis of the glucose concentration. Repeating this uncomfortable and painful task 4-8 times per day leads to severe loss in life quality, often resulting in poor compliance leading to costly complications.
RSP’s proprietary non-invasive SMBG technology relies on the capabilities of Raman spectroscopy for directly detecting individual substances, refined by a unique critical depth optical scanning to collect glucose signals from the right tissue depth range, thus avoiding sources of errors during the measurement. Our GlucoBeam device will enable DM patients to test their glucose levels in around 30s and as often as desired – at no added cost or pain – thereby empowering them to better manage their treatment and minimizing the risk for acute complications.
GlucoBeam’s successful commercialization will position RSP to secure an aggregated turnover of approx. €253 million over the 5 years post-project period. Furthermore, it has the potential to reach double digit billion savings for EU’s healthcare systems and will ultimately lead to significantly improved life quality for the large population of diabetic patients. Moreover, GlucoBeam’s commercialization will allow RSP to set a market foothold in order to leverage its medium term innovation strategy.
|Project website||Websites, patent fillings, videos etc.||2019-05-31 10:46:14|
Take a look to the deliverables list in detail: detailed list of GlucoBeam deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLUCOBEAM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GLUCOBEAM" are provided by the European Opendata Portal: CORDIS opendata.
CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical researchRead More
SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.Read More
Delivering BEACON Caresystem – a ground-breaking ICT-enabled ICU bed-side assistant providing recommenda-tions for critical mechanical ventilation support for better care and reduced costs.Read More